Adverum Biotechnologies (ADVM) Gets a Hold Rating from Chardan Capital

By Ryan Adsit

Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Adverum Biotechnologies (ADVMResearch Report) today and set a price target of $10. The company’s shares closed last Monday at $13.40.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 17.9% and a 48.5% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Axovant Gene Therapies, and VistaGen Therapeutics.

Currently, the analyst consensus on Adverum Biotechnologies is a Moderate Buy with an average price target of $12.

See today’s analyst top recommended stocks >>

The company has a one-year high of $16.38 and a one-year low of $2.62. Currently, Adverum Biotechnologies has an average volume of 1.11M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich’s ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.